Dr Reddy's Laboratories realigns its Global Generics business

26-Mar-2009

Dr Reddy's Laboratories has refocused its Global Generics finished dosages business to focus on certain key areas and will gradually pull out of some of the "very small" distributor-driven markets, which make an overall contribution of less than 1% to the topline.

Dr Reddy's Laboratories has refocused its Global Generics finished dosages business to focus on certain key areas and will gradually pull out of some of the "very small" distributor-driven markets, which make an overall contribution of less than 1% to the topline.

In addition to the US, India, Russia & CIS and Germany, where operations already contribute approximately 90% of Global Generics revenues, the company will continue to operate in 10-15 markets where finished dosages sales are "growing significantly".

The company said the move would reduce the complexity of operations while helping to improve customer service and grow market share.

Satish Reddy, md and COO of Dr Reddy's, said: "We intend aggressively to step up our presence in our key markets with this strategic prioritisation. The company will however continue to scan opportunities and attractiveness of international markets in line with its business strategy."

Sign up for your free email newsletter

Established in 1984, Dr. Reddy's Laboratories produces finished dosage forms, active pharmaceutical ingredients and biotechnology products. The company conducts research in the areas of cancer, diabetes, cardiovascular, inflammation and bacterial infection.

Companies